Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:35 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,687 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo twice/day Clear all

Conditions: Fibromyalgia
Interventions: Placebo, Milnacipran 100mg; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 1,025 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 24
States / cities: Tuscaloosa, Alabama • Fresno, California • Pismo Beach, California + 20 more

Conditions: Nicotine Dependence
Interventions: Placebo, Varenicline; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 65 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Alzheimer's Disease
Interventions: ABT-957, Placebo for ABT-957; Drug · Other
Lead sponsor: AbbVie; Industry
Eligibility: 55 Years to 90 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 4
States / cities: Glendale, California • Orlando, Florida • New York, New York + 1 more

Conditions: Schizophrenia
Interventions: NaBen®, Placebo; Drug
Lead sponsor: SyneuRx International (Taiwan) Corp; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 20
States / cities: Dothan, Alabama • Bellflower, California • Long Beach, California + 17 more

Conditions: Diabetes Mellitus, Type 2
Interventions: PF-05190457 or Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Brain Concussion
Interventions: Branched Chain Amino Acids, Placebo solution; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 11 Years to 34 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Alcohol Use Disorder
Interventions: Topiramate, placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 70 Years
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 2
States / cities: Decatur, Georgia • Philadelphia, Pennsylvania

Conditions: Asthma, Atopy
Interventions: fluticasone, Placebo; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 9
States / cities: San Francisco, California • Denver, Colorado • Chicago, Illinois + 6 more

Conditions: Asthma
Interventions: Ciclesonide (XRP1526); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years and older
Enrollment: 456 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Asthma
Interventions: BI 671800, Placebo, Montelukast; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 243 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 6
States / cities: Denver, Colorado • North Dartmouth, Massachusetts • Plymouth, Minnesota + 3 more

Conditions: Postherpetic Neuralgia
Interventions: ADL5747, Placebo, Pregabalin; Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 75 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: West Palm Beach, Florida

Conditions: Healthy
Interventions: JTK-853, ketoconazole, JTK-853 or Placebo; Drug
Lead sponsor: Shionogi Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Fatigue
Interventions: Muscadine grape extract, Placebo, Quality of Life Assessment, Questionnaires, Participant Feedback; Dietary Supplement · Drug · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 65 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Neoplasm of Pancreas, IPMN, Pancreatic
Interventions: Vitamin E Delta Tocotrienol, Placebo; Drug · Other
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Tampa, Florida • Omaha, Nebraska

Conditions: Smoking, Nicotine Dependence
Interventions: Naltrexone, Bupropion; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: HIV, Salivary Gland Disease, Benign Lymphoepithelial Lesion
Interventions: Ciprofloxacin, Placebo; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Systemic Lupus Erythematosus
Interventions: Mycophenolate Mofetil, Placebo for Mycophenolate Mofetil, Voclosporin, Placebo for Voclosporin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 10
States / cities: Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 6 more

Conditions: Smell Dysfunction, Olfactory Disorder, Long COVID
Interventions: Trigeminal Nerve Stimulation (TNS), Active Smell Training (ST), Placebo Smell Training (PBO); Device · Other
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 65 Years
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: COVID-19
Interventions: Cetirizine, Famotidine, Cetirizine Placebo, Famotidine Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 4
States / cities: Atlanta, Georgia

Conditions: Atopic Dermatitis
Interventions: Placebo, JNJ-26113100 (50 mg) once daily, JNJ-26113100 (100 mg) once daily, JNJ-26113100 (100 mg) twice daily, JNJ-26113100 (250 mg) twice daily; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 19
States / cities: Huntsville, Alabama • Los Angeles, California • Sacramento, California + 16 more

Conditions: Chronic Pain, Pain, Opioid Withdrawal (Disorder), Opioid Use Disorder
Interventions: Cebranopadol, Placebo; Drug
Lead sponsor: Adneuris Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: North Canton, Ohio • Houston, Texas

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neurotoxicity, Pain, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: baclofen/amitriptyline/ketamine gel, placebo; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 165
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Aurora, Illinois + 104 more

Conditions: Atopic Dermatitis
Interventions: EDP1815, Placebo; Drug
Lead sponsor: Evelo Biosciences, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 421 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 27
States / cities: Birmingham, Alabama • Fountain Valley, California • Fremont, California + 22 more

Conditions: Alzheimer Disease
Interventions: Salsalate, Placebo; Drug
Lead sponsor: Adam Boxer; Other
Eligibility: 50 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 2
States / cities: San Diego, California • San Francisco, California

Search by objective public record fields.

Study of Milnacipran for the Treatment of Fibromyalgia

Effects of Chantix on Relapse Prevention for Smoking Cessation

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen®

A Study Of PF-05190457 In Healthy Volunteers And Type-2 Diabetic Patients

BCAA Supplementation for Concussion

Topiramate Treatment of Alcohol Use Disorders in African Americans

Airway Microbiome in Asthma: Relationships to Asthma Phenotype and Inhaled Corticosteroid Treatment

Efficacy of Ciclesonide Versus Placebo Administered Either as Once Daily or Twice Daily in Patients Treated Previously With an Inhaled Corticosteroid

BI 671800 in Asthmatic Patients on Inhaled Corticosteroids

Study to Assess the Efficacy, Safety, and Tolerability of ADL5747 in Participants With Postherpetic Neuralgia

Two Week Study Evaluating Safety, Tolerability and Pharmacokinetics of Multiple Doses of JTK-853 in Healthy Subjects

Muscadine Grape Extract to Improve Fatigue

Study of IPMN Progression Prevention With Tocotrienol (SIPP-T3)

Low-Dose Naltrexone Combined With Bupropion to Stop Smoking With Less Weight Gain

BK Virus in Salivary Gland Disease: Treating the Potential Etiologic Agent

Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus

Study of Chemosensory Enhancement Through Neuromodulation Training (SCENT for Long COVID)

Treatment of Long CoronaVirus Disease (COVID) (TLC) Feasibility Trial

An Efficacy and Safety Study of JNJ-26113100 in the Treatment of Adult Atopic Dermatitis

A Study of Cebranopadol for Opioid Withdrawal Symptoms in Adults With Chronic Pain

Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer

A Study Investigating the Effect of EDP1815 in the Treatment of Mild, Moderate and Severe Atopic Dermatitis

Salsalate in Patients Mild to Moderate Alzheimer's Disease